Search
Antihemophilic factor (recombinant), PEGylated
go.drugbank.com/drugs/DB09329ApprovedInvestigationalAntihemophilic Factor (Recombinant), PEGylated, was approved by the FDA in December 2016 as the product Adynovate [FDA label]. Antihemophilic Factor (Recombinant), PEGylated, is a recombinant full-length human coagulation factor VIII (2,...
Products: ADYNOVATE 500®IU / VIAL, ADYNOVATE®250IU/VIALFactor IX Complex (Human)
go.drugbank.com/drugs/DB11330ApprovedInvestigationalFactor IX Complex is a sterile, lyophilized concentrate composed of a number of Vitamin K-dependent clotting factors found in functioning human plasma. Also known as prothrombin complex concentrate, products containing this complex often...
Mixtures: Bebulin Vh Inj 1000unit/vialProducts: Bebulin Vh 500unit/vial, Alphanine Pws Inj 1500unit/vialCeftriaxone
go.drugbank.com/drugs/DB01212ApprovedInvestigationalCeftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for
Mixtures: ROCEPHIN VIAL 500MG IM, ROCEPHIN VIAL 1G IMCategories: P-glycoprotein inhibitorsMedroxyprogesterone acetate
go.drugbank.com/drugs/DB00603ApprovedInvestigationalMedroxyprogesterone acetate (MPA) is a progesterone derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: DEPO-PROVERA 150 INJ (3ML,VIAL), Condep Injection 50mg/ml (3ml vial)Botulinum toxin type A
go.drugbank.com/drugs/DB00083ApprovedInvestigationalIn 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum to...
Products: Powder for Solution for Injection 50 Units/Vial, Powder for Solution for Injection 200 Units/VialTriptorelin
go.drugbank.com/drugs/DB06825ApprovedInvestigationalVet approvedTriptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous ad...
Synonyms: (D-Trp6)-GnRH, pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2Products: POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION 3.75 mg/vial, POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION 11.25 mg/vialTirzepatide
go.drugbank.com/drugs/DB15171ApprovedInvestigationalTirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight co...
Products: Mounjaro 5 mg solution for injection in vial, Mounjaro 10 mg solution for injection in vialDoripenem
go.drugbank.com/drugs/DB06211ApprovedWithdrawnDoripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections. In a clinical t...
Products: DORIBAX® VIAL, REDIDOR 500 MG /VIALRemdesivir
go.drugbank.com/drugs/DB14761ApprovedInvestigationalSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress s...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: COVIFOR (REMDESIVIR FOR INJECTION 100MG/VIAL), VEKLURY® LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIALAflibercept
go.drugbank.com/drugs/DB08885ApprovedInvestigational[A261281,A261286] Due to the 2 fused VEGFR, aflibercept has a higher affinity to the cognate ligands than the endogenous individual receptor. … [L47976] An aflibercept biosimilar, Yesafili, was approved for use in the EU in September 2023.
Products: EYLEA SOLUTION FOR INJECTION IN VIAL 2MG, EYLEA 40MG/ML SOLUTION FOR INJECTION IN VIAL